person · Reporting owner

POTTER MYRTLE S

Disclosed activity across 12 companies

Tapewire entity: 13295
SEC CIK: 0001214130

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMAZON COM INCAMZN · Entity 1956	Director	April 12, 2009	April 13, 2009
Arbutus Biopharma CorpABUS · Entity 4953	Director	August 17, 2019	August 20, 2019
Axsome Therapeutics, Inc.AXSM · Entity 2469	Director	June 07, 2019	June 10, 2019
Guardant Health, Inc.GH · Entity 3238	Director	June 22, 2026	June 23, 2026
INSMED IncINSM · Entity 3174	Director	May 15, 2018	May 17, 2018
Immunovant, Inc.IMVT · Entity 3632	Director	December 18, 2019	December 20, 2019
NEW RITE AID, LLCRAD · Entity 87704	Director	October 03, 2017	October 05, 2017
Sio Gene Therapies Inc.AXGT · Entity 130622	Director	April 15, 2019	April 18, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMAZON COM INC

Report date April 12, 2009 · Filed April 13, 2009

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.01 per shareSEC Table I · non-derivative	Direct	6,500	Reported balance After 2009-04-12 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2009-04-12 · Exercise / conversion · Acquired 2,500 · Balance 6,500 F1: By trust.
Common Stock, par value $.01 per shareSEC Table I · non-derivative	Direct	2,883	Reported balance Holding disclosure · report date 2009-04-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,883
Restricted Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2009-04-12	Direct	0	Reported balance After 2009-04-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-04-12 · Exercise / conversion · Disposed 2,500 · Balance 0 F2: Converts into Common Stock on a one-for-one basis. F3: Subject to the reporting person's continued service as a director of the issuer, this award vested and converted into shares of common stock of the issuer at the rate of 60% on April 12, 2007, an additional 20% on April 12, 2008 and an additional 20% on April 12, 2009.

Filing footnotes · ownership attribution and instrument terms

F1: By trust.

F2: Converts into Common Stock on a one-for-one basis.

F3: Subject to the reporting person's continued service as a director of the issuer, this award vested and converted into shares of common stock of the issuer at the rate of 60% on April 12, 2007, an additional 20% on April 12, 2008 and an additional 20% on April 12, 2009.

Arbutus Biopharma Corp

Report date August 17, 2019 · Filed August 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2029-08-17	Direct	22,000	Reported balance After 2019-08-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-08-17 · Grant · Acquired 22,000 · Balance 22,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant.

Axsome Therapeutics, Inc.

Report date June 07, 2019 · Filed June 10, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.03 · Expires 2029-06-07	Direct	13,000	Reported balance After 2019-06-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-07 · Grant · Acquired 13,000 · Balance 13,000 F1: The option vests in full on the one-year anniversary of the date of grant, June 7, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the one-year anniversary of the date of grant, June 7, 2020.

Guardant Health, Inc.

Report date June 22, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,971	Reported balance After 2026-06-22 transaction · row 1 1 source row Row 1 · 2026-06-22 · Sale · Disposed 1,556 · Balance 20,971

INSMED Inc

Report date May 15, 2018 · Filed May 17, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,510	Reported balance After 2018-05-15 transaction · row 1 1 source row Row 1 · 2018-05-15 · Grant · Acquired 6,066 · Balance 25,510 F1: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date.

F2: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock.

Immunovant, Inc.

Report date December 18, 2019 · Filed December 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.86 · Expires 2029-06-19	Direct	137,617	Reported balance After 2019-12-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-12-18 · Grant · Acquired 137,617 · Balance 137,617 F2: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd. (the "Business Combination Transaction"), the option to purchase 281,387 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.86 · Expires 2029-07-28	Direct	893	Reported balance After 2019-12-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-18 · Grant · Acquired 893 · Balance 893 F3: In connection with the Business Combination Transaction, the option to purchase 1,825 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-10-20	Direct	11,488	Reported balance After 2019-12-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-18 · Grant · Acquired 11,488 · Balance 11,488 F4: In connection with the Business Combination Transaction, the option to purchase 23,489 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-11-19	Direct	3,765	Reported balance After 2019-12-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-18 · Grant · Acquired 3,765 · Balance 3,765 F5: In connection with the Business Combination Transaction, the option to purchase 7,698 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.

F2: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd. (the "Business Combination Transaction"), the option to purchase 281,387 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).

F3: In connection with the Business Combination Transaction, the option to purchase 1,825 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

F4: In connection with the Business Combination Transaction, the option to purchase 23,489 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

F5: In connection with the Business Combination Transaction, the option to purchase 7,698 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

NEW RITE AID, LLC

Report date October 03, 2017 · Filed October 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	78,790	Reported balance After 2017-10-03 transaction · row 1 1 source row Row 1 · 2017-10-03 · Sale · Disposed 28,189 · Balance 78,790 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.09 to $2.095, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.09 to $2.095, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Sio Gene Therapies Inc.

Report date April 15, 2019 · Filed April 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-04-14	Direct	255,000	Reported balance After 2019-04-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-04-15 · Grant · Acquired 255,000 · Balance 255,000 F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Everyday Health, Inc.

Report date December 03, 2016 · Filed December 06, 2016

Section 16 reporting ended · disclosed 2016-12-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2016-12-05 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2016-12-03 · Other · Disposed 2,008 · Balance 16,375 F1: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company (the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). Row 2 · 2016-12-05 · Disposition to issuer · Disposed 16,375 · Balance 0 F2: Pursuant to the terms of the award, the vesting of restricted stock units for an aggregate of 16,375 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35	Direct	Reported balance After 2016-12-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-12-05 · Disposition to issuer · Disposed 23,333 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.87	Direct	Reported balance After 2016-12-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-12-05 · Disposition to issuer · Disposed 23,333 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.68	Direct	Reported balance After 2016-12-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-12-05 · Disposition to issuer · Disposed 27,978 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company (the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").

F2: Pursuant to the terms of the award, the vesting of restricted stock units for an aggregate of 16,375 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding).

F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).

Ginkgo Bioworks Holdings, Inc.

Report date June 11, 2025 · Filed June 13, 2025

Section 16 reporting ended · disclosed 2025-06-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	10,822	Reported balance After 2025-06-11 transaction · row 1 1 source row Row 1 · 2025-06-11 · Exercise / conversion · Acquired 10,822 · Balance 10,822 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2025-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-11 · Exercise / conversion · Disposed 10,822 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 13, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 13, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.

Myovant Sciences Ltd.

Report date March 10, 2023 · Filed March 10, 2023

Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-03-10 transaction · row 1 1 source row Row 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.17 · Expires 2028-09-19	Direct	Reported balance After 2023-03-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-10 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22	Direct	Reported balance After 2023-03-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-10 · Disposition to issuer · Disposed 58,608 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14	Direct	Reported balance After 2023-03-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04	Direct	Reported balance After 2023-03-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.

F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").

F4: These options are fully vested.

F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

Urovant Sciences Ltd.

Report date March 29, 2021 · Filed March 31, 2021

Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-03-29 · Disposition to issuer · Disposed 12,480 · Balance 0 F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-03-29 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2028-11-21	Direct	Reported balance After 2021-03-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-29 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2029-07-09	Direct	Reported balance After 2021-03-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-29 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2030-07-21	Direct	Reported balance After 2021-03-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-03-29 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 15, 2022 Filed Dec 20, 2022 22:09 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-22-000120 · wf-form4_167157412490282.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
December 15, 2022 Filed Dec 20, 2022 22:09 UTC	Guardant Health, Inc. GH · Entity 3238	GrantRESTRICTED STOCK UNITS	68	$0.00	$0.00	Disclosure SEC source: 0001576280-22-000120 · wf-form4_167157412490282.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957 Read SEC document
November 15, 2022 Filed Nov 17, 2022 22:49 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-22-000108 · wf-form4_166872532701686.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,394 Underlying: COMMON STOCK · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
November 15, 2022 Filed Nov 17, 2022 22:49 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS	69	$0.00	$0.00	Disclosure SEC source: 0001576280-22-000108 · wf-form4_166872532701686.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 26, 2022 Filed Oct 28, 2022 20:36 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantCommon Shares	9,859	$0.00	$0.00	Disclosure SEC source: 0001209191-22-054812 · doc4.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,859 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person as the annual non-employee director grant. The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time. F2 · shares: Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the "Merger Agreement"). Read SEC document
October 15, 2022 Filed Oct 18, 2022 20:25 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	820	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-22-000085 · wf-form4_166612471981077.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,463 Underlying: COMMON STOCK · 820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
October 15, 2022 Filed Oct 18, 2022 20:25 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS	820	$0.00	$0.00	Disclosure SEC source: 0001576280-22-000085 · wf-form4_166612471981077.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2022 Filed Jun 17, 2022 22:05 UTC	Guardant Health, Inc. GH · Entity 3238	GrantRESTRICTED STOCK UNITS · Derivative	5,531	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-22-000048 · wf-form4_165550350544417.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,531 Underlying: COMMON STOCK · 5,531 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest in full on the one-year anniversary of the grant date, June 15th, 2023. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
June 15, 2022 Filed Jun 17, 2022 22:05 UTC	Guardant Health, Inc. GH · Entity 3238	GrantSTOCK OPTION (RIGHT TO BUY) · Derivative	8,789	$0.00 Strike: $38.42	$0.00	Disclosure SEC source: 0001576280-22-000048 · wf-form4_165550350544417.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,789 Underlying: COMMON STOCK · 8,789 shares Expires 2032-06-14 F1 · derivative.exercise_date: The Stock Options vest in full on the one-year anniversary of the grant date, June 15th, 2023. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:32 UTC	Guardant Health, Inc. GH · Entity 3238	GrantSTOCK OPTION (RIGHT TO BUY) · Derivative	5,613	$0.00 Strike: $110.43	$0.00	Disclosure SEC source: 0001576280-21-000106 · wf-form4_163658353555237.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,613 Underlying: COMMON STOCK · 5,613 shares Expires 2031-11-07 F3 · derivative.exercise_date: The stock option vest as to 25% of the shares subject to such award on October 15, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. Read SEC document
November 08, 2021 Filed Nov 10, 2021 22:32 UTC	Guardant Health, Inc. GH · Entity 3238	GrantRESTRICTED STOCK UNITS · Derivative	3,283	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-21-000106 · wf-form4_163658353555237.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,283 Underlying: COMMON STOCK · 3,283 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable to Restricted Stock Units. Read SEC document
November 05, 2021 Filed Nov 9, 2021 22:26 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantStock Option (Right to Buy) · Derivative	21,096	$0.00 Strike: $22.71	$0.00	Disclosure SEC source: 0001209191-21-063672 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,096 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) November 5, 2022, and (b) the date that is one day prior to the Issuer's 2022 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0000899243-21-014101 · doc4.xml · derivative · entry 5 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,000 shares Expires 2030-07-21 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0000899243-21-014101 · doc4.xml · derivative · entry 4 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2029-07-09 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $8.01	$0.00	Disclosure SEC source: 0000899243-21-014101 · doc4.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2028-11-21 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerCommon Shares	9,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-014101 · doc4.xml · nonDerivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerCommon Shares	12,480	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-014101 · doc4.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
September 15, 2020 Filed Sep 17, 2020 20:13 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantStock Option (Right to Buy) · Derivative	21,603	$0.00 Strike: $21.47	$0.00	Disclosure SEC source: 0001209191-20-050876 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,603 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:31 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0001209191-20-043482 · doc4.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2030-07-21 F2 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:31 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantCommon Shares	9,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-043482 · doc4.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,480 F1 · shares: The Restricted Stock Units shall vest on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
January 10, 2020 Filed Jan 14, 2020 21:07 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantCommon Shares	12,480	$0.00	$0.00	Disclosure SEC source: 0001209191-20-003285 · doc4.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,480 F1 · shares: The Restricted Stock Units shall vest on January 10, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:57 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	3,765	Not disclosed Strike: $8.43	Not disclosed	Disclosure SEC source: 0001209191-19-061598 · doc4.xml · derivative · entry 4 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,765 Underlying: Common Stock · 3,765 shares Expires 2029-11-19 F5 · price: In connection with the Business Combination Transaction, the option to purchase 7,698 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:57 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	11,488	Not disclosed Strike: $8.43	Not disclosed	Disclosure SEC source: 0001209191-19-061598 · doc4.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,488 Underlying: Common Stock · 11,488 shares Expires 2029-10-20 F4 · price: In connection with the Business Combination Transaction, the option to purchase 23,489 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:57 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	893	Not disclosed Strike: $7.86	Not disclosed	Disclosure SEC source: 0001209191-19-061598 · doc4.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 Underlying: Common Stock · 893 shares Expires 2029-07-28 F3 · price: In connection with the Business Combination Transaction, the option to purchase 1,825 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:57 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	137,617	Not disclosed Strike: $7.86	Not disclosed	Disclosure SEC source: 0001209191-19-061598 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,617 Underlying: Common Stock · 137,617 shares Expires 2029-06-19 F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd. (the "Business Combination Transaction"), the option to purchase 281,387 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter. Read SEC document
August 23, 2019 Filed Aug 27, 2019 20:46 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantStock Option (Right to Buy) · Derivative	58,608	$0.00 Strike: $7.65	$0.00	Disclosure SEC source: 0001209191-19-047531 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,608 Underlying: Common Shares · 58,608 shares Expires 2029-08-22 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 23, 2020, and (b) the date that is one day prior to the Issuer's 2020 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document
August 17, 2019 Filed Aug 20, 2019 20:17 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantStock Options · Derivative	22,000	$0.00 Strike: $1.50	$0.00	Disclosure SEC source: 0001447028-19-000056 · wf-form4_156633224863367.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. Read SEC document
July 09, 2019 Filed Jul 11, 2019 17:15 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0001209191-19-041791 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2029-07-09 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable on July 9, 2020, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
June 07, 2019 Filed Jun 10, 2019 22:20 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $22.03	$0.00	Disclosure SEC source: 0001104659-19-034642 · a4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 7, 2020. Read SEC document
April 15, 2019 Filed Apr 18, 2019 01:19 UTC	Sio Gene Therapies Inc. AXGT · Entity 130622	GrantStock Option (Right to Buy) · Derivative	255,000	$0.00 Strike: $1.06	$0.00	Disclosure SEC source: 0001209191-19-025194 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document
November 21, 2018 Filed Nov 27, 2018 01:40 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $8.01	$0.00	Disclosure SEC source: 0000899243-18-029671 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2028-11-21 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on November 9, 2019, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document
October 18, 2018 Filed Oct 22, 2018 17:37 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantDirector Share Option (Right to Buy) · Derivative	44,000	$0.00 Strike: $4.71	$0.00	Disclosure SEC source: 0001567619-18-004380 · doc1.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Shares · 44,000 shares Expires 2028-10-18 F1 · derivative.exercise_date: The options vest as follows: 1/3 on 10/18/2019; 1/3 on 10/18/2020; and 1/3 on 10/18/2021. Read SEC document
October 15, 2018 Filed Oct 16, 2018 22:05 UTC	Sio Gene Therapies Inc. AXON · Entity 130622	GrantStock Option ( Right to Buy) · Derivative	150,000	$0.00 Strike: $2.37	$0.00	Disclosure SEC source: 0001209191-18-055181 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2028-10-14 F1 · derivative.exercise_date: The common shares underlying this option vest over a period of three years, with one-third of the common shares vesting on each of the first, second and third anniversaries of September 26, 2018, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document
September 20, 2018 Filed Sep 24, 2018 20:42 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantStock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $26.17	$0.00	Disclosure SEC source: 0001209191-18-052044 · doc4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-09-19 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on September 20, 2019, with the balance of the shares vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document
June 01, 2018 Filed Jun 6, 2018 00:20 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	GrantStock Options (right to buy) · Derivative	4,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001104659-18-038398 · a4.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2027-06-15 F2 · derivative.exercise_date: The option will vest 1/3 on June 16, 2018, 1/3 on June 16, 2019 and 1/3 on June 16, 2020. Read SEC document
June 01, 2018 Filed Jun 6, 2018 00:20 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	GrantStock Options (right to buy) · Derivative	13,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001104659-18-038398 · a4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-01 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 1, 2019. Read SEC document
May 15, 2018 Filed May 17, 2018 20:15 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,066	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-18-000042 · edgar.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,510 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock. Read SEC document
October 03, 2017 Filed Oct 5, 2017 16:34 UTC	NEW RITE AID, LLC RAD · Entity 87704	SaleCommon Stock	28,189	$2.09	$58,915.01	Disclosure SEC source: 0001209191-17-056134 · doc4.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,790 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.09 to $2.095, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document
July 17, 2017 Filed Jul 21, 2017 17:33 UTC	NEW RITE AID, LLC RAD · Entity 87704	GrantCommon Stock	51,984	$0.00	$0.00	Disclosure SEC source: 0001710635-17-000012 · primary_doc.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,979 Read SEC document
June 16, 2017 Filed Jun 19, 2017 20:23 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	GrantStock Option (Right to Buy) · Derivative	8,197	$0.00 Strike: $4.10	$0.00	Disclosure SEC source: 0001104659-17-040183 · a4.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,197 Underlying: Common Stock · 8,197 shares Expires 2027-06-15 F2 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 16, 2018. Read SEC document
June 16, 2017 Filed Jun 19, 2017 20:23 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $4.10	$0.00	Disclosure SEC source: 0001104659-17-040183 · a4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: The option will vest in equal annual installments over three years such that the option will be fully vested on June 16, 2020. Read SEC document
May 17, 2017 Filed May 19, 2017 20:30 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,702	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-17-000045 · edgar.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,444 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was received as a grant on May 17, 2017, and represents a contingent right to receive one share of Common Stock. Read SEC document
December 14, 2016 Filed Dec 15, 2016 14:07 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	5,000	$12.77	$63,845.00	Disclosure SEC source: 0001127430-16-000167 · edgar.xml · nonDerivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.75 to $12.81, inclusive. Read SEC document
December 13, 2016 Filed Dec 15, 2016 14:07 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	1,466	$12.88	$18,886.48	Disclosure SEC source: 0001127430-16-000167 · edgar.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.88 to $12.91, inclusive. Read SEC document
December 05, 2016 Filed Dec 6, 2016 22:46 UTC	Everyday Health, Inc. EVDY · Entity 180558	Disposition to issuerStock Option (Right to Buy) · Derivative	27,978	$2.82 Strike: $7.68	$78,897.96	Disclosure SEC source: 0001209191-16-153724 · doc4.xml · derivative · entry 5 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,978 shares Expires not disclosed F3 · kind: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · price: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). Read SEC document
December 05, 2016 Filed Dec 6, 2016 22:46 UTC	Everyday Health, Inc. EVDY · Entity 180558	Disposition to issuerStock Option (Right to Buy) · Derivative	23,333	$1.64 Strike: $8.87	$38,149.46	Disclosure SEC source: 0001209191-16-153724 · doc4.xml · derivative · entry 4 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,333 shares Expires not disclosed F3 · kind: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · price: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). Read SEC document
December 05, 2016 Filed Dec 6, 2016 22:46 UTC	Everyday Health, Inc. EVDY · Entity 180558	Disposition to issuerStock Option (Right to Buy) · Derivative	23,333	$4.16 Strike: $6.35	$96,948.62	Disclosure SEC source: 0001209191-16-153724 · doc4.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,333 shares Expires not disclosed F3 · kind: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · price: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). Read SEC document
December 05, 2016 Filed Dec 6, 2016 22:46 UTC	Everyday Health, Inc. EVDY · Entity 180558	Disposition to issuerCommon Stock	16,375	$10.50	$171,937.50	Disclosure SEC source: 0001209191-16-153724 · doc4.xml · nonDerivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the terms of the award, the vesting of restricted stock units for an aggregate of 16,375 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding). F2 · price: Pursuant to the terms of the award, the vesting of restricted stock units for an aggregate of 16,375 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding). Read SEC document
December 03, 2016 Filed Dec 6, 2016 22:46 UTC	Everyday Health, Inc. EVDY · Entity 180558	OtherCommon Stock	2,008	$10.50	$21,084.00	Disclosure SEC source: 0001209191-16-153724 · doc4.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,375 F1 · kind: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company (the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). F1 · price: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company (the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). Read SEC document
April 12, 2009 Filed Apr 13, 2009 20:30 UTC	AMAZON COM INC AMZN · Entity 1956	Exercise / conversionRestricted Stock Unit Award · Derivative	2,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001359804-09-000017 · edgar.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.01per share · 2,500 shares Expires 2009-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converts into Common Stock on a one-for-one basis. F3 · derivative.exercise_date: Subject to the reporting person's continued service as a director of the issuer, this award vested and converted into shares of common stock of the issuer at the rate of 60% on April 12, 2007, an additional 20% on April 12, 2008 and an additional 20% on April 12, 2009. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.